Methodological constraints in interpreting serum paraoxonase-1 activity measurements: an example from a study in HIV-infected patients
© Parra et al; licensee BioMed Central Ltd. 2010
Received: 24 February 2010
Accepted: 25 March 2010
Published: 25 March 2010
Paraoxonase-1 (PON1) is an antioxidant enzyme that attenuates the production of the monocyte chemoattractant protein-1 (MCP-1) in vitro. Although oxidation and inflammation are closely related processes, the association between PON1 and MCP-1 has not been completely characterised due, probably, to that the current use of synthetic substrates for PON1 measurement limits the interpretation of the data. In the present study, we explored the relationships between the circulating levels of PON1 and MCP-1 in human immunodeficiency virus-infected patients in relation to the multifunctional capabilities of PON1.
We measured selected variables in 227 patients and in a control group of 409 participants. Serum PON1 esterase and lactonase activities were measured as the rates of hydrolysis of paraoxon and of 5-(thiobutyl)-butyrolactone, respectively. Oxidised LDL and MCP-1 concentrations were determined by enzyme-linked immunosorbent assay. High-density lipoproteins cholesterol, apolipoprotein A-I, and C-reactive protein concentrations were measured by standard automated methods.
There were significant relationships between PON1 activity and several indices of oxidation and inflammation in control subjects and in infected patients. However, these relationships varied not only with disease status but also on the type of substrate used for PON1 measurement.
The present study is a cautionary tale highlighting that results of clinical studies on PON1 may vary depending on the methods used as well as the disease studied. Until more specific methods using physiologically-akin substrates are developed for PON1 measurement, we suggest the simultaneous employment of at least two different substrates in order to improve the reliability of the results obtained.
Paraoxonase-1 (PON1) is an enzyme with esterase and lactonase activities found in the circulation bound to high-density lipoproteins (HDL). Research into PON1 has increased exponentially over the past few years because many studies associate this enzyme with inflammation and cardiovascular disease. The physiological substrates of PON1 have not been completely delineated, but in vitro studies suggest that a key function is to degrade oxidised phospholipids in low-density lipoproteins (LDL) and HDL and, as such, has an antioxidant role . PON1 attenuates the production of the monocyte chemoattractant protein-1 (MCP-1) in cultured endothelial cells. MCP-1 is a pro-inflammatory chemokine involved in the initial steps in the formation of the atheromatous plaque . Previous studies from our group have shown that HIV-infected patients have decreased serum PON1 activities and increased plasma MCP-1 concentrations, and that certain genetic polymorphisms of both molecules are associated with the presence of sub-clinical atherosclerosis [3–5]. Although oxidation and inflammation are closely related processes, the association between PON1 and MCP-1 has not been completely characterised. This is probably due, at least in part, to the limitations of the current methods of measuring serum PON1 activity i.e. the current use of synthetic substrates limits the interpretation of the data since it is not clear to what extent these measured activities reflect the real endogenous physiological activity of the enzyme.
The present study was aimed at extending our observations on the relationships between the circulating levels of PON1 and MCP-1 in HIV-infected patients. Using two assay methods for the different enzyme activities (esterase and lactonase), we sought to evaluate possible discrepancies relating to the analytical methods (different substrates) employed.
We studied 227 HIV-infected patients and 409 healthy volunteers. The exclusion criteria for the patients were age ≤ 18 years, and having an AIDS-related disease. The clinical characteristics of these patients have been previously published . The study was approved by the Ethics Committee of Hospital Universitari de Sant Joan de Reus (Catalonia).
Serum PON1 esterase activity was measured as the hydrolysis of the substrate paraoxon , and the lactonase activity was measured as the hydrolysis of the substrate 5-(thiobutyl)-butyrolactone (TBBL) . HDL-cholesterol and apolipoprotein A-I were analysed by standard methods (Beckman-Coulter, Fullerton, CA, USA), oxidised LDL and MCP-1 by enzyme-linked immunosorbent assay (Mercodia, Uppsala, Sweden, and Prepotech, London, UK, respectively), and C-reactive protein (CRP) by a high sensitivity immunoturbidimetric method (Beckman-Coulter).
Normality of distributions was tested with the Kolmogorov-Smirnov test. We used Spearman's (ρ) test to identify correlations between variables, and curve estimation analyses when non-linear correlations were found. Statistical analyses were performed with the SPSS 17.0 statistical package. Results are presented as means (SD).
Results of the biochemical measurements
PON1 esterase activity, U/L
PON1 lactonase activity, U/L
Apolipoprotein A-I, g/L
Oxidised LDL, U/L
C-reactive protein, mg/L
We observed a significant curvilinear relationship between serum PON1 lactonase activity and oxidised LDL (p = 0.003) in HIV-infected patients (Figure 1C), but not in the control group. Conversely, lactonase activity was significantly related to MCP-1 in the control subjects (linear; ρ = 0.208; p = 0.002) but not in HIV-infected patients (Figure 1D). We also found significant associations between serum PON1 lactonase activity and apolipoprotein A-I (linear; ρ = 0.281; p < 0.001) and CRP (curvilinear; p = 0.027) in HIV-infected patients, but not in the control group.
The present study presents a puzzling picture in that the observed relationships between PON1 activity and several indices of oxidation and inflammation depended not only on the HIV infection but also on the substrate used to measure PON1. Methods using the non-physiological paraoxon as substrate have traditionally been used to measure PON1 activities, the levels of which have been proposed as indicators in the prediction of cardiovascular disease . Recently, the lactonase activity assay using TBBL has been developed and evaluated [7, 8] and, although TBBL is also a synthetic substrate, it probably measures an activity that is closer to the physiological state, since it represents a chemical reaction that is lactone-degrading and, as such, is probably closer to the physiological basis of PON1 activity. Experimental evidence suggests that, essentially, the lactonase assay measures PON1 that is tightly bound to HDL particles, while the esterase assay measures the tightly as well as the loosely bound enzyme . The differences between methods, therefore, could also be related to the observed changes in structure and composition of the HDL particles during HIV infection. These changes may be due to the chronic inflammation per se, or to secondary effects of the antiretroviral treatments . There is the possibility that these changes affect PON1 activity and that this is further influenced by the type of substrate used to measure PON1. We acknowledge that the different relationships observed between PON1 activities and MCP-1 in HIV-infected patients may, possibly, not be extrapolated to non-diseased control subjects. Nevertheless, the wide distribution of PON1 in different cell types and co-localisation with MCP-1 in most tissues  suggests a fundamental association between these two molecules in the regulation of oxidation and inflammation.
We conclude with a cautionary note to researchers conducting clinical studies on PON1; the experimental findings can vary, as in the present study, depending on the methods of measurement used, and the disease studied. Until more specific methods using physiologically-akin substrates are developed for PON1 measurement, the simultaneous employment of at least two different substrates to measure PON1 activity would be the recommended so that the reliability of the results may be improved.
human immunodeficiency virus
monocyte chemoattractant protein-1
We thank Dr. Dan Tawfik, Olga Khersonsky and Leonid Gaidukov, from the Weizmann Institute of Science (Rehovolt, Israel) for the gift of the TBBL reagent. This study was funded by grants from the ISCIII, Madrid, Spain (PI 081175 and PI081381). Editorial assistance was provided by Dr. Peter Turner (t-SciMed, Reus, Spain).
- Camps J, Marsillach J, Joven J: The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci. 2009, 46: 83-96. 10.1080/10408360802610878View ArticlePubMed
- Alonso-Villaverde C, Coll B, Parra S, Montero M, Calvo N, Tous M, Joven J, Masana L: Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation. 2004, 110: 2204-2209. 10.1161/01.CIR.0000143835.95029.7DView ArticlePubMed
- Parra S, Alonso-Villaverde C, Coll B, Ferré N, Marsillach J, Aragonès G, Mackness M, Masana L, Joven J, Camps J: Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. Atherosclerosis. 2007, 194: 175-81. 10.1016/j.atherosclerosis.2006.07.024View ArticlePubMed
- Parra S, Marsillach J, Aragonés G, Beltrán R, Montero M, Coll B, Mackness B, Mackness M, Alonso-Villaverde C, Joven J, Camps J: Paraoxonase-1 gene haplotypes are related to metabolic disturbances, atherosclerosis and immunologic outcome in HIV-infected patients. J Infect Dis. 2010, 201: 627-634. 10.1086/650312View ArticlePubMed
- Coll B, Parra S, Alonso-Villaverde C, Aragonès G, Montero M, Camps J, Joven J, Masana L: The role of immunity in the progression of atherosclerosis in patients with HIV infection. Stroke. 2007, 38: 2477-2484. 10.1161/STROKEAHA.106.479030View ArticlePubMed
- Eckerson HW, Wyte CM, La Du BN: The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet. 1983, 35: 1126-1138.PubMed CentralPubMed
- Gaidukov L, Tawfik DS: The development of human sera test for HDL-bound serum PON1 and its lipolactonase activity. J Lipid Res. 2007, 48: 1637-1646. 10.1194/jlr.D600045-JLR200View ArticlePubMed
- Marsillach J, Aragonès G, Beltrán R, Caballeria J, Pedro-Botet J, Morcillo-Suárez C, Navarro A, Joven J, Camps J: The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. Clin Biochem. 2009, 42: 91-8. 10.1016/j.clinbiochem.2008.09.120View ArticlePubMed
- Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Hama S, Hough G, Bachini E, Grijalva VR, Wagner AC, Shaposhnik Z, Fogelman AM: The double jeopardy of HDL. Ann Med. 2005, 37: 173-78. 10.1080/07853890510007322View ArticlePubMed
- Marsillach J, Mackness B, Mackness M, Riu F, Beltrán R, Joven J, Camps J: Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Rad Biol Med. 2008, 45: 146-157. 10.1016/j.freeradbiomed.2008.03.023View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.